Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) EBT (2017 - 2026)

Kiniksa Pharmaceuticals International filings provide 6 years of EBT readings, the most recent being $32.7 million for Q1 2026.

  • On a quarterly basis, EBT rose 109.96% to $32.7 million in Q1 2026 year-over-year; TTM through Mar 2026 was $106.0 million, a 7675.79% increase, with the full-year FY2025 number at $88.9 million, up 412.06% from a year prior.
  • EBT hit $32.7 million in Q1 2026 for Kiniksa Pharmaceuticals International, up from $23.3 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $46.7 million in Q3 2022 to a low of -$88.3 million in Q4 2022.
  • Median EBT over the past 5 years was -$7.2 million (2024), compared with a mean of -$4.8 million.
  • Biggest five-year swings in EBT: crashed 118.19% in 2023 and later surged 892.93% in 2025.
  • Kiniksa Pharmaceuticals International's EBT stood at -$88.3 million in 2022, then increased by 18.38% to -$72.0 million in 2023, then skyrocketed by 87.08% to -$9.3 million in 2024, then soared by 350.07% to $23.3 million in 2025, then soared by 40.45% to $32.7 million in 2026.
  • The last three reported values for EBT were $32.7 million (Q1 2026), $23.3 million (Q4 2025), and $27.2 million (Q3 2025) per Business Quant data.